The prevailing excitement in the scientific and medical community about 'liquid biopsy', a minimally invasive diagnostic involving body fluid, is understandable, since it has the possibility of detecting pre-malignant and early-stage cancers, and enables the assessment of response to treatments [1] . Supplementing previous techniques that sample circulating cell-free tumor DNA, tumor cells, and microvesicles [2], a recent work has shown using RNA-seq data that tumor-educated platelets (TEP) can distinguish 228 patients with localized and metastasized tumors from 55 healthy individuals with 96% accuracy [3] . However, as demonstrated in the current work, over-expression of MET genes in nonsmall cell lung carcinoma (NSCLC), and HER2/ERBB2 genes in breast cancer are grossly misreported. Based on an analysis of a smaller subset of samples, it is shown that there is little, leave alone overexpression, of these genes in the samples with the specified disease. Confirmation that this is bonafide platelet mRNA is provided by high levels of the platelet marker TMSB4X. A kmer-based method (k=32) has been used here (KEATS) to detect homologous transcripts, although the results are easily verified by a BLAST search -BLAST'ing the MET gene (Accid: NM 001127500.2) to a NSCLC sample (https://trace.ncbi.nlm.nih.gov/Traces/sra/?run=SRR1982781) shows almost no expression. This is in contrast to expected expression of the MET gene in another a NSCLC sample (SRR3475320) from another sample. Similar contradictions apply for HER2/ERBB2 genes with respect to breast cancer samples. This work emphasizes the neccessity of a more stringent verification framework for bioinformatic analyses, and raises serious doubts on using TEP as a possible 'liquid biopsy' candidate.
Introduction
Tumor tissue biopsy, the gold standard for cancer diagnostics, pose challenges that include access to the tumor, quantity and quality of tumoral material, lack of patient compliance, repeatability, and bias of sampling a specfic area of a single tumor [4] . This has resulted in a new medical and scientific paradigm defined by minimal invasiveness, high-efficiency, low-cost diagnostics [5] , and, whenever possible, personalized treatment based on genetic and epigenetic composition [6] . The presence of fragmented DNA in the cell-free component of whole blood (cfDNA) [7] , first reported in 1948 by Mandel and Metais, has been extensively researched for decades, with extremely promising results in certain niches [8] . Additionally, cfDNA derived from tumors (ctDNA) [9] have tremendous significance as a cancer diagnostic tool [10] , and for monitoring responses to treatment [11] . However, detection of ctDNA, and differentiation with cfDNA, remains a challenge due the low amounts of ctDNA compared to cfDNA [1] .
Recently, tumor-educated blood platelets (TEP) were proposed as an alternative source of tumor-related biological information [3, 12] . The hypothesis driving the potential diagnostic role of TEPs is based on the interaction between blood platelets and tumor cells, subsequently altering the RNA profile of platelets [13, 14] . The study showed using RNA-seq data that tumor-educated platelets (TEP) can distinguish 228 patients with localized and metastasized tumors from 55 healthy individuals with 96% accuracy [3] . As validation, this study reported significant over-expression of MET genes in non-small cell lung carcinoma (NSCLC), and HER2/ERBB2 [15] genes in breast cancer, which are well-established biomarkers. Here, analysis of a subset of the samples refutes the claims of over-expression of MET and HER2/ERBB2 genes, in TEP. The rational expression profile of MET genes in another NSCLC sample (SRA:SRR3475320) from a different study, and the high counts of the platelet marker TMSB4X in the current study (also mentioned in the TEP study) further validates the discrepancy noted here. These results are easily verified by a BLAST search.
Contradictory results:
A smaller subset of lung cancer samples (DATASET:list.lung.txt,n=24) was used from the given 60 NSCLC samples in the TEP study [3] . Table 1 shows very little expression of the MET gene (Accid: NM 001127500.2) in these samples. In contrast, the RNA-seq sample from a NSCLC female patient (SRA:SRR3475320) from a different study shows reasonable expression (Table 1) . A BLAST search also shows (graphically) a rational expression pattern (Fig 2) . In fact, there is very little MET expression in any sample (cancer of any kind or healthy) in a random subset of 119 samples (DATASET:list.119.txt). Another verification is provided by the high level of expression of the TMSB4X gene (Fig 3) , which has also been detected and mentioned in the TEP study as a platelet marker [3] . Similar contradictions apply for HER2 genes with respect to breast cancer samples (Fig 4) .
Conclusion:
This raises serious doubts on using TEP as a possible 'liquid biopsy' candidate. Essentially, it refutes the hypothesis that platelets carry enough RNA-seq from tumors to make it viable as a diagnostic method. A review found it 'surprising' that although 'the tumor type was the predominant factor for the actual platelet conditioning, tumor metastasis did not significantly impact on them when compared to samples from patients without metastasis' [14] . The excitement surrounding the fact that '2016 marked the first approval of a liquid biopsy test in oncology to assist in patient selection for treatment' [16] should be tempered, and a cautious approach adopted [17, 18] with reports of 'broken promises' [19] .
Finally, the current study highlights the neccessity of a more stringent verification framework for bioinformatic analyses in large scale studies [20, 21] . The black-box surrounding bioinformatic analyses should be made more transparent.
Materials and methods
A kmer-based version (KEATS [22] ) of YeATS [20, [23] [24] [25] [26] was used to obtain gene counts from transcripts in the RNA-seq data. A BLAST search suffices to demonstrate the absence of MET genes in the lung cancer samples. 
